Myocarditis
Also known as: Inflammatory Cardiomyopathy
Myocarditis is an inflammation of the heart muscle (myocardium), most commonly caused by viral infections, that can reduce the heart's ability to pump blood and cause abnormal heart rhythms. It ranges from mild, self-resolving illness to fulminant disease requiring mechanical circulatory support or heart transplantation. Myocarditis is an important cause of sudden cardiac death in young athletes.
Last updated November 10, 2026
Understanding Myocarditis
Myocarditis is inflammation of the heart muscle, most often set off by a viral infection, and it is one of the few heart conditions that mainly strikes young, otherwise healthy people. Estimated incidence is 10 to 20 cases per 100,000 people a year, roughly 1.5 to 2 million cases worldwide, though many mild cases are never diagnosed because the symptoms are put down to the flu. It is most common between 20 and 40, affects men about twice as often as women, and accounts for about 5 to 10 percent of sudden cardiac deaths in young athletes. COVID-19 infection raised the risk sharply: in a CDC analysis of more than 36 million hospital records, people with COVID-19 were about 16 times more likely to be diagnosed with myocarditis than those without. mRNA vaccine myocarditis is real but much rarer and milder, peaking at about 1 in 10,000 doses in males aged 16 to 17 after the second dose, usually 2 to 3 days later, with 87 percent symptom-free by hospital discharge.
Injury happens in phases. In the first days a virus (classically coxsackievirus, adenovirus, parvovirus B19 or SARS-CoV-2) or a toxin damages heart muscle cells directly. The immune response that follows, over 1 to 4 weeks, does much of the harm: T cells and antibodies attack infected and sometimes healthy muscle, which is why the chest pain, rhythm problems and pump failure often appear as the fever fades. The heart then either heals or scars. Roughly half of people recover fully within 2 to 4 weeks, about a quarter are left with some persistent weakness of the heart muscle, and 12 to 25 percent deteriorate quickly or progress over months to dilated cardiomyopathy. Exercise during the inflammatory phase is dangerous for a specific reason: in animal studies it increases viral replication, inflammation and death, and in people it is the setting in which myocarditis causes sudden arrhythmic death. Chest pain, breathlessness, palpitations or fainting within a few weeks of a viral illness is an emergency until proven otherwise.
Diagnosis starts in the emergency department with an ECG, a troponin blood test, usually BNP and CRP, and an echocardiogram; a raised troponin in a young person without coronary risk factors should prompt cardiac MRI, which uses the 2018 updated Lake Louise criteria to show swelling and scar without a biopsy. Endomyocardial biopsy is reserved for people with shock, heart block, ventricular arrhythmias or failure to improve, because it changes treatment when it finds giant cell myocarditis, sarcoidosis or eosinophilic disease. Treatment is supportive for most viral cases: rest, and standard heart failure drugs (ACE inhibitors or ARBs, beta-blockers, mineralocorticoid antagonists) if the pumping fraction falls, continued until the heart recovers. Immunosuppression is life-saving in giant cell myocarditis, where combination therapy roughly quadrupled median transplant-free survival in the original registry, and high-dose steroids are started urgently for myocarditis from immune checkpoint inhibitors, which kills 25 to 50 percent of those affected. Fulminant cases need intensive care and temporary mechanical support. AHA/ACC (2015) and European Society of Cardiology (2020) guidelines require 3 to 6 months away from competitive and vigorous exercise.
There is no natural treatment for myocarditis, and supplements that promise to fight the virus or strengthen the heart are a distraction. The supportive measures that have evidence apply mostly to people left with heart failure. Coenzyme Q10 reduced major cardiac events from 26 to 15 percent over 2 years in the 420-person Q-SYMBIO heart failure trial; 1 g of omega-3 daily lowered deaths by about 9 percent in the 6,975-person GISSI-HF trial; and correcting a measured vitamin D deficiency improved pumping function in one trial. Astragalus has been tested for viral myocarditis in Chinese trials, but a 2013 Cochrane review found them too poorly designed to draw any conclusion. Some common products are harmful here. Ibuprofen and other NSAIDs taken for the chest pain worsened inflammation and survival in animal myocarditis and are avoided when the heart muscle is involved; licorice root lowers potassium and raises blood pressure; and stimulants (ephedra, bitter orange, high-caffeine pre-workout powders, energy drinks) can provoke dangerous arrhythmias in an inflamed heart. Clear every product, including herbal teas, with the cardiology team.
The most common mistake is going back to training too early. Young, fit people feel better long before the heart has healed, and the inflammation that triggers fatal arrhythmias is invisible from the outside, which is why return-to-play decisions rest on repeat tests, not on how you feel. The standard sequence, 3 to 6 months after the illness, is an echocardiogram or MRI showing normal pumping function, a troponin back in the normal range, and a 24-hour Holter monitor plus an exercise stress test free of significant arrhythmias. Only then does a cardiologist clear a gradual return, usually starting with light activity and building over weeks. The second mistake is stopping heart failure medication once energy returns, before the follow-up scan confirms the heart has recovered. Go to the emergency department, or call 911, for chest pain, fainting, a racing or pounding heartbeat, breathlessness lying flat, or new leg swelling at any point during recovery; a relapse in the first year happens in a minority but is just as dangerous as the first episode.
At a Glance
- Common symptoms
- Chest pain, Shortness of breath, at rest or with exertion, Rapid or irregular heartbeat (palpitations, arrhythmias)
- Main treatments
- Supportive care and activity restriction until inflammation resolves, Heart failure medications (ACE inhibitors, beta-blockers, diuretics) as needed, Immunosuppressive therapy for giant cell myocarditis and autoimmune causes
- Category
- Cardiovascular · Estimated 10–20 cases per 100,000 people per year
- See a doctor if
- Chest pain with shortness of breath, especially after a recent viral illness
Symptoms
Causes
- Viral infections (coxsackievirus B, adenovirus, parvovirus B19, SARS-CoV-2, influenza)
- Autoimmune and inflammatory conditions (giant cell myocarditis, sarcoidosis, lupus)
- Medications and toxins (immune checkpoint inhibitors, certain chemotherapy drugs, cocaine)
- Bacterial, fungal, or parasitic infections (less common)
Risk Factors
- Young adults and athletes
- Recent viral illness
- Autoimmune diseases
- HIV/AIDS
- Cancer treatment with immune checkpoint inhibitors
Diagnosis
- Cardiac MRI with gadolinium enhancement (preferred non-invasive test — Lake Louise criteria)
- Troponin and BNP/NT-proBNP blood tests (elevated in myocardial injury/heart failure)
- Echocardiogram to assess heart function
- ECG showing ST changes, arrhythmias, or conduction abnormalities
- Endomyocardial biopsy (gold standard, but rarely performed unless giant cell myocarditis or unclear diagnosis)
Treatment
- Supportive care and activity restriction until inflammation resolves
- Heart failure medications (ACE inhibitors, beta-blockers, diuretics) as needed
- Immunosuppressive therapy for giant cell myocarditis and autoimmune causes
- Antiarrhythmic medications or temporary pacing for significant arrhythmias
- Mechanical circulatory support (ECMO, ventricular assist device) for fulminant cases
- Avoidance of competitive sports for 3–6 months (per ACC/AHA guidelines)
Natural remedies for myocarditis: what the evidence says
Ranked by the strength of human evidence for myocarditis specifically. These sit alongside medical care, not in place of it.
Coenzyme Q10
Preliminary evidenceThere is no trial of coenzyme Q10 in adult viral myocarditis; small pediatric studies from China are of low quality. The relevant evidence is for heart failure that can follow myocarditis: in the 2-year Q-SYMBIO trial of 420 people with moderate to severe heart failure, 100 mg three times daily reduced major adverse cardiac events from 26 to 15 percent and cardiovascular deaths from 16 to 9 percent. It takes 3 to 6 months to show any effect.
- Studied dose
- 100 mg two to three times daily with food (ubiquinone or ubiquinol), only once the acute phase is over and with the cardiologist's agreement.
- Cautions
- Reduces the effect of warfarin; can lower blood pressure further alongside heart failure drugs; mild stomach upset. Not for the acute or fulminant phase, and never a reason to delay hospital care.
Omega-3
Preliminary evidenceNo myocarditis trial exists. In GISSI-HF, 6,975 people with chronic heart failure randomized to 1 g of omega-3 daily had 9 percent fewer deaths and 8 percent fewer deaths or heart failure admissions over 3.9 years. Higher omega-3 status is linked to fewer ventricular arrhythmias in observational work, but large trials of 4 g daily in heart disease found more atrial fibrillation, so the heart failure dose of 1 g is the one to discuss.
- Studied dose
- 1 g daily of combined EPA and DHA (prescription or third-party-tested fish oil) if left with reduced pumping function.
- Cautions
- Doses of 4 g a day increased atrial fibrillation in two large trials and add to bleeding with anticoagulants. Fishy burps are common; stop a week before any procedure if advised.
Vitamin D
Preliminary evidenceVitamin D deficiency is common in heart failure and in people recovering from a long illness indoors. In the VINDICATE trial, 229 people with heart failure and low vitamin D who took 4,000 IU daily for a year improved left ventricular ejection fraction by about 6 percentage points and reduced heart size compared with placebo, though walking distance did not improve. No trial has tested it in myocarditis itself.
- Studied dose
- 1,000 to 4,000 IU vitamin D3 daily, guided by a 25-hydroxyvitamin D blood test.
- Cautions
- High doses raise calcium, which increases arrhythmia risk alongside digoxin or thiazide diuretics; have calcium checked if you take more than 2,000 IU daily.
Astragalus
Preliminary evidenceAstragalus is widely used for viral myocarditis in China. A 2013 Cochrane review identified 20 randomized trials, most of astragalus injections or granules in children, reporting fewer arrhythmias and faster normalization of cardiac enzymes, but every trial was small, unblinded or at high risk of bias, and the reviewers concluded there is no reliable evidence of benefit or harm.
- Studied dose
- Studied as 10 to 30 g dried root in decoction or standardized extract capsules of 500 mg two or three times daily; oral forms only.
- Cautions
- Stimulates immune activity, so avoid in giant cell, sarcoid or checkpoint-inhibitor myocarditis and with any immunosuppressant; may interact with lithium and cyclophosphamide. Discuss with the cardiologist before use.
What matters day to day
- Stop all moderate and vigorous exercise, including gym sessions, running and competitive sport, for 3 to 6 months from diagnosis, and restart only after a cardiologist clears you on the basis of a normal echocardiogram or MRI, normal troponin, a Holter monitor and an exercise test: exercise during inflammation is the setting in which myocarditis causes sudden death.
- Avoid alcohol completely while recovering: alcohol is directly toxic to heart muscle, weakens pumping function and raises the chance of atrial fibrillation and other arrhythmias in an irritable heart.
- Weigh yourself each morning if you have been told your heart is weakened: a gain of more than 2 to 3 pounds in a day or 5 pounds in a week means fluid is building, and your team should know the same day.
- Keep sodium below about 2 g (5 g of salt) a day and follow any fluid limit if you have heart failure symptoms: this lowers the work the healing heart has to do and reduces swelling and breathlessness.
- Do not take ibuprofen, naproxen or high-dose aspirin for the chest pain; use acetaminophen and ask the cardiologist about colchicine if the pain is coming from the pericardium, the sac around the heart, which is often inflamed at the same time.
- Once recovered, keep up influenza and COVID-19 vaccination unless your cardiologist advises otherwise: influenza infection is itself a documented cause of myocarditis and of heart attacks in the weeks after infection, and the infection risk outweighs the vaccine risk.
Prevention
- Avoid vigorous exercise during and shortly after viral illnesses
- Prompt treatment of infections
- Influenza and COVID-19 vaccination (benefits outweigh myocarditis risk)
When to See a Doctor
- Chest pain with shortness of breath, especially after a recent viral illness
- Rapid or irregular heartbeat with lightheadedness
- New onset of fatigue and exercise intolerance
- Leg swelling with breathing difficulty
Frequently Asked Questions
References
- Kociol RD, Cooper LT, Fang JC, et al.. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation (2020)
- Ammirati E, Frigerio M, Adler ED, et al.. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circulation: Heart Failure (2020)
- Maron BJ, Udelson JE, Bonow RO, et al.. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. Circulation (2015)
- Pelliccia A, Sharma S, Gati S, et al.. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal (2021)
- Ferreira VM, Schulz-Menger J, Holmvang G, et al.. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. Journal of the American College of Cardiology (2018)
- Boehmer TK, Kompaniyets L, Lavery AM, et al.. Association between COVID-19 and myocarditis using hospital-based administrative data, United States, March 2020 to January 2021. MMWR Morbidity and Mortality Weekly Report (2021)
- Oster ME, Shay DK, Su JR, et al.. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA (2022)
- Mortensen SA, Rosenfeldt F, Kumar A, et al.. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO, a randomized double-blind trial. JACC: Heart Failure (2014)
- Liu ZL, Liu ZJ, Liu JP, Kwong JS. Herbal medicines for viral myocarditis. Cochrane Database of Systematic Reviews (2013)
- MedlinePlus Medical Encyclopedia. Myocarditis (2024)
Related Conditions
Lab tests that relate to myocarditis
Have questions about Myocarditis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.